Movement Disorders (revue) - Exploration (Accueil)

Index « Keywords » - entrée « Dyskinesia, Drug-Induced (drug therapy) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Dyskinesia, Drug-Induced (diagnosis) < Dyskinesia, Drug-Induced (drug therapy) < Dyskinesia, Drug-Induced (enzymology)  Facettes :

List of bibliographic references indexed by Dyskinesia, Drug-Induced (drug therapy)

Number of relevant bibliographic references: 75.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000390 (2014) Erwan Bezard [République populaire de Chine] ; Elsa Y. Pioli ; Qin Li ; Françoise Girard ; Vincent Mutel ; Charlotte Keywood ; Francois Tison ; Olivier Rascol ; Sonia M. PoliThe mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
000628 (2014) Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. FacherisCombined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
000678 (2014) Danhui Zhang [États-Unis] ; Tanuja Bordia [États-Unis] ; Matthew Mcgregor [États-Unis] ; J. Michael Mcintosh [États-Unis] ; Michael W. Decker [États-Unis] ; Maryka Quik [États-Unis]ABT-089 and ABT-894 Reduce L-Dopa-Induced Dyskinesias in a Monkey Model of Parkinson’s Disease
000695 (2013) Olga Waln [États-Unis] ; Joseph Jankovic [États-Unis]Zolpidem improves tardive dyskinesia and akathisia.
000767 (2013) Erwan Bezard [France] ; Elisabetta Tronci ; Elsa Y. Pioli ; Qin Li ; Gregory Porras ; Anders Björklund ; Manolo CartaStudy of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
000885 (2013) Maryka Quik ; Archana Mallela ; Jason Ly ; Danhui ZhangNicotine reduces established L-dopa-induced dyskinesias in a monkey model of Parkinson’s disease
000B23 (2013) Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia TrenkwalderAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
001309 (2011) James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada]The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease
001363 (2011) Christopher Kobylecki [Royaume-Uni] ; Michael P. Hill [Canada] ; Alan R. Crossman [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni, Canada]Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
001591 (2011) P. Stathis [Grèce] ; S. Konitsiotis [Grèce] ; G. Tagaris [Grèce] ; D. Peterson [Finlande]Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease
001780 (2011) Alberto J. Espay [États-Unis] ; Jennifer E. Vaughan [États-Unis] ; Rakesh Shukla [États-Unis] ; Maureen Gartner [États-Unis] ; Alok Sahay [États-Unis] ; Fredy J. Revilla [États-Unis] ; Andrew P. Duker [États-Unis]Botulinum toxin type A for Levodopa‐induced cervical dyskinesias in Parkinson's disease: Unfavorable risk‐benefit ratio
001828 (2011) Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Iiona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Thérèse Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse]AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials
001833 (2011) Kitty K. Wong [Australie] ; Jane E. Alty [Australie] ; Amanda G. Goy [Australie] ; Sanjay Raghav [Australie] ; David C. Reutens [Australie] ; Peter A. Kempster [Australie]A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease
001944 (2010) Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada]The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates
001B63 (2010) Sara Varanese [États-Unis, Italie] ; Jonathan Howard [États-Unis] ; Alessandro Di Rocco [États-Unis]NMDA antagonist memantine improves levodopa‐induced dyskinesias and “On‐off” phenomena in Parkinson's disease
001C02 (2010) Elisabeth Wolf [Autriche] ; Klaus Seppi [Autriche] ; Regina Katzenschlager [Autriche] ; Guenter Hochschorner [Autriche] ; Gerhard Ransmayr [Autriche] ; Petra Schwingenschuh [Autriche] ; Erwin Ott [Autriche] ; Iris Kloiber [Autriche] ; Dietrich Haubenberger [Autriche] ; Eduard Auff [Autriche] ; Werner Poewe [Autriche]Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease
002621 (2008) Robert A. Hauser [États-Unis] ; Lisa M. Shulman [États-Unis] ; Joel M. Trugman [États-Unis] ; John W. Roberts [États-Unis] ; Akihisa Mori [Japon] ; Rocco Ballerini [États-Unis] ; Neil M. Sussman [États-Unis]Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
002D66 (2007) Christopher Kenney [États-Unis] ; Christine Hunter [États-Unis] ; Joseph Jankovic [États-Unis]Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
003143 (2006) Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada]Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure
003277 (2006) Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
003339 (2006) Izchak Kohen [Niger, États-Unis] ; Adnan Sarcevic [États-Unis]Mirtazapine in bupropion‐induced dyskinesias: A case report

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Dyskinesia, Drug-Induced (drug therapy)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Dyskinesia, Drug-Induced (drug therapy)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Dyskinesia, Drug-Induced (drug therapy)
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024